Section 21: Power of Central Authority to issue directions and penalties against false or misleading advertisements

Consumer Protection Act • Official Statutory Text & Practice Guide

Statutory Regulation
Legal Standard
Competent Court / Tribunal
Act 2019

Legal Commentary & Landmark Judgments: Section 21

Section 21 vests the Central Consumer Protection Authority with far-reaching enforcement and punitive powers against traders, manufacturers, advertisers, publishers, and celebrity endorsers who disseminate false or misleading advertisements. It establishes a multi-tiered regulatory regime capable of directing modification/withdrawal, imposing heavy financial penalties up to Rs. 50 Lakhs, and disqualifying celebrity endorsers, while embedding precise statutory safe harbours based on due diligence and ordinary course of business.

  • Corrective Directions and Financial Penalties: Under Section 21(1)-(2), CCPA may direct discontinuance/modification of misleading ads, and impose penalties on manufacturers or endorsers up to Rs. 10 Lakhs for a first contravention, and up to Rs. 50 Lakhs for each subsequent contravention.
  • Endorser Disqualification and Statutory Due Diligence Safe Harbour: Section 21(3) authorizes CCPA to prohibit an endorser from endorsing any product/service for up to 1 year (up to 3 years for subsequent contraventions). Crucially, Section 21(5) provides complete immunity to the endorser if they prove they exercised due diligence to verify the veracity of the claims made.
  • Publisher Immunity and Four-Factor Penalty Assessment: Section 21(6) protects publishers who published ads in the ordinary course of business without prior knowledge of a CCPA withdrawal order. Section 21(7) mandates that penalties must be determined by assessing four statutory factors: population/area impacted, frequency/duration of offence, vulnerability of the affected class, and gross sales revenue derived.
Key Landmark Precedents:
  • Havells India Ltd. v. Amritanshu Khaitan (2015) 219 DLT 194: The Delhi High Court held that while honest comparative advertising is permissible, an advertisement that misleads, misrepresents, or disparages competing goods or conceals material limitations violates consumer trust and constitutes an unfair trade practice.
  • Indian Medical Association v. Union of India (Patanjali Ayurved Contempt Proceedings, 2024 SC): The Supreme Court emphasized the critical statutory obligation under consumer protection and drug advertising laws to penalize false claims regarding medicinal cures and misleading endorsements that exploit vulnerable consumers.
  • Colgate Palmolive (India) Ltd. v. Hindustan Unilever Ltd. (1999) 7 SCC 1: The Supreme Court established that advertising claims must be evaluated from the perspective of an ordinary consumer with reasonable prudence; unsubstantiated scientific claims constitute actionable deception.
Courtroom Practice & Strategic Litigation Guidance:

For celebrity endorsers and brand ambassadors, defense under Section 21 hinges entirely on documenting due diligence under Section 21(5). Retain a formal verification dossier: accredited third-party laboratory test certificates, regulatory approvals (e.g., FSSAI/AYUSH licenses), and written representations from the manufacturer. For manufacturers challenging the quantum of penalty, plead that the CCPA failed to properly apply the four mitigating criteria in Section 21(7), especially where the reach of the campaign was limited or no actual consumer injury occurred.